Immunohistochemical detection of p21ras, c-myc and p53 oncoproteins in hepatocellular carcinoma and in non-neoplastic liver tissue;Detecção imunoistoquímica das oncoproteínas p21ras, c-myc e p53 no carcinoma hepatocelular e no tecido hepático não-neoplásico

Arquivos de Gastroenterologia

Volumn 41, Issue 4, 2004, Pages 225-228

  Pannain, Vera Lucia Nunes ^a,c   Bottino, Adriana Caroli ^a   Santos, Raimunda Telma M ^b   Coelho, Henrique Sérgio M ^a   Ribeiro Filho, Joaquim ^a   Alves, Venâncio A F ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Lab Imunoistoquim Inst Adolfo L   (Brazil)

^c Faculdade de Medicina da UFRJ ^*  (Brazil)

Author keywords

Carcinoma, hepatocellular; Immunohistochemistry; Liver, pathology; Oncogene protein; Oncogene protein p21 (ras); Protein p53

Indexed keywords

MYC PROTEIN; PROTEIN P21; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPIGENETICS; HEPATITIS B; HEPATITIS C; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PROTEIN ANALYSIS;

EID: 16444366243     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032004000400005     Document Type: Article

References (32)

1. Abou-Elella A, Gramlich T, Fritsch C, Gansler T. C-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. Mod Pathol 1996;9:95-8.
2. Alves VAF, Carrilho FJ, Wakamatsu A, Laudanna AA, Silva LC, Gayotto LCC. Immunohistochemistry of p53 in hepatocellular carcinoma in São Paulo, Brasil. Hepatology 1994;19:391.
3. Arbuthnot P, Kew M, Fitschen W. C-fos and c-myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res 1991;11:921-4.
4. Challen C, Lunek J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor-supressor gene in hepatocellular carcinomas from Britain. Hepatology 1992;16:1362-6.
5. Dominguez-Malagón H, Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol 2001;25:497-516.
6. Fausto N, Shank PR. Oncogen expression in liver regeneration and hepatocarcinogenesis. Hepatology 1983;3:1016-23.
7. Hirohashi S, Ishak KG, Kojiro M, Wanless IR, Theise ND, Tsukuma H, Blum HE, Deugnier Y, Laurent Puig P, Fischer HP, Sakamoto M. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, editors. Tumors of the digestive system. Lyon: IARC Press; 2000. p. 159-72.
8. Huber BE, Thorgeirsson SS. Analysis of c-myc expression in a human hepatoma cell line. Cancer Res 1987;47:3414-20.
9. Ishikawa F, Takaku F, Hayashi K, Nagao M, Sugimura T. Activation of rat c-raf during transfection of hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1986;83:3209-12.
10. Kawate S, Fukusato T, Ohwada S, Watunuki A, Morishita Y. Amplification of c-myc in hepatocellular carcinoma: correlate with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 1999;57:157-63.
11. Kress S, Jahn UR, Buchmann A, Bannash P, Schwarz M. P53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 1992;52:3220-3.
12. Kubicka S, Trautwein C, Schrem H, Tilmann H, Manns M. Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 1995;23:412-9.
13. Lee HS, Rajagopalan MS, Vyas GN. A lack of direct role of hepatitis B virus in the activation of ras and myc oncogenes in human hepatocellular carcinogenesis. Hepatology 1988;8:1116-20.
14. Loke SL, Neckers LM, Schwab G, Jaffe ES. C-myc protein in normal tissue. Effects of fixation on its apparent subcellular distribution. Am J Pathol 1988;131:29-37.
15. Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma. Hum Pathol 1995;26:326-33.
16. Nishida N, Fukuda Y, Kokuryu H, Toguchida J, Yandell DW, Ikenega M, Imura H, Ishizaki K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res 1993;53:368-72.
17. Nita ME, Alves VA, Carrilho FJ, Ono-Nita SK, Mello ES, Gama-Rodrigues JJ. Molecular aspects of hepatic carcinogenesis. Rev Inst Med Trop Sao Paulo 2002;44:38-48.
18. Nonomura A; Ohta G; Hayashi M; Izumi R; Watanabe K; Takayanagi N; Mizukami Y; Matsubara F. Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 1987;82:512-8.
19. Ogata N, Kamikura T, Asakura H. Point mutation, allelic loss and increased methylation of c-Ha-ras gene in human hepatocellular carcinoma. Hepatology 1991;13:31-7.
20. Ojanguren I, Anza A, Castella E, Fernandez VA, Matt JL, Navas-Palacios JJ. P53 immunoreactivity in hepatocellular adenoma, focal nodular hyperplasia, cirrhosis and hepatocellular,carcinoma. Histopathology 1995;26:63-8.
21. Ozturk M. P53 hotspot mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991;338:1356-9.
22. Pasquanelli C, Bhavani K, Chisari FV. Multiple oncogenes and tumor supressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. Cancer Res 1992;52:2823-9.
23. Pereira LMB, Mies S, Rydei ID, Leitão MR, Raia S. Mutação do p53 no carcinoma hepatocelular [resumo]. In: Anais do 12o Congresso Brasileiro de Hepatologia; 1993. p.43.
24. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995;37:209-20.
25. Scorsone KA, Zhou YZ, Butel JS, Slagle BL. P53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 1992;52:1635-8.
26. Sinha S, Webber C, Marshall CJ, Knowles MA, Proctor A, Barrass NC, Neal GE. Activation of ras oncogene in an afiatoxin-induced rat liver carcinogenesis. Proc Natl Acad Sci USA 1988;85:3673-7.
27. Tashiro F, Morimura S, Hayashi K, Makino R, Kawamura H, Horikoshi N, Nemoto K, Ohtsubo K, Sugimura T, Ueno Y. Expression of the c-Ha-ras and c-myc genes in aflatoxin-B1 induced hepatocellular carcinomas. Biochem Biophys Res Commun 1986 138:858-64.
28. Tiniakos D, Spandidos DA, Kakkanas A, Pintzas A, Pollice L, Tiniakos G. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissue. Anticancer Res 1989;9:715-22.
29. Tiniakos D, Spandidos DA, Yagnisis M, Tiniakos G. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease. Hepatogastroenterology 1992;40:37-40.
30. Volkmann M, Hoffmann HJ, Meyer M, Hayashi IC, Maeda S. P53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994;9:195-204.
31. Wee A, Teh M, Raju GC. P53 expression in hepatocellular carcinoma in a population in Singapore with endemic hepatitis B virus infection. J Clin Pathol 1995;48:236-8.
32. Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-myc, c-fos and c-jun in hepatocellular carcinoma. Cancer 2001;91:106-12.